FCGR3A and rheumatoid arthritis: Jiménez Morales et al. [96] aimed to evaluate the effects of FCGR2A rs1801274 and FCGR3A rs396991 gene polymorphisms on response to RTX, EULAR response, remission, low disease activity (LDA), and DAS28 improvement in 55 patients diagnosed with RA and treated with RTX for 6, 12, and 18 months.